De novo induction of antigen‐specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR
暂无分享,去创建一个
[1] R. Negrin,et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. , 2008, Blood.
[2] Wenda Gao,et al. Reciprocal generation of Th1/Th17 and Treg cells by B1 and B2 B cells , 2007, European journal of immunology.
[3] D. Fuchs,et al. Regulatory T-Cell Markers, Indoleamine 2,3-Dioxygenase, and Virus Levels in Spleen and Gut during Progressive Simian Immunodeficiency Virus Infection , 2007, Journal of Virology.
[4] A. Mondino,et al. mTOR at the crossroads of T cell proliferation and tolerance. , 2007, Seminars in immunology.
[5] W. Sandborn,et al. Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.
[6] A. Rudensky,et al. Foxp3 in control of the regulatory T cell lineage , 2007, Nature Immunology.
[7] L. Boon,et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells , 2007, Bone Marrow Transplantation.
[8] Tianfu Wu,et al. PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. , 2007, International immunology.
[9] V. Kuchroo,et al. Contrasting Effects of Cyclosporine and Rapamycin in De Novo Generation of Alloantigen‐Specific Regulatory T Cells , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] M. Baccarani,et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. , 2007, Blood.
[11] T. Whiteside,et al. Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1 , 2007, The Journal of Immunology.
[12] M. Farrar,et al. IL-2 Receptor β-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells1 , 2007, The Journal of Immunology.
[13] R. Truitt,et al. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. , 2007, Cytotherapy.
[14] M. Battaglia,et al. Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 , 2006, The Journal of Immunology.
[15] U. Grohmann,et al. Tryptophan catabolism generates autoimmune-preventive regulatory T cells. , 2006, Transplant immunology.
[16] C. Chougnet,et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. , 2006, Blood.
[17] Shile Huang,et al. Predicted mechanisms of resistance to mTOR inhibitors , 2006, British Journal of Cancer.
[18] M. Arias,et al. Calcineurin Inhibitors, but not Rapamycin, Reduce Percentages of CD4+CD25+FOXP3+ Regulatory T Cells in Renal Transplant Recipients , 2006, Transplantation.
[19] L. Ignatowicz,et al. Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. , 2006, Immunity.
[20] C. Chougnet,et al. Do regulatory T-cells play a role in AIDS pathogenesis? , 2006, AIDS reviews.
[21] B. Kyewski,et al. Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] M. Sadelain,et al. Cutting Edge: CD28 Controls Dominant Regulatory T Cell Activity during Active Immunization1 , 2006, The Journal of Immunology.
[23] V. Basso,et al. Prolonged TCR/CD28 Engagement Drives IL-2-Independent T Cell Clonal Expansion through Signaling Mediated by the Mammalian Target of Rapamycin1 , 2006, The Journal of Immunology.
[24] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[25] P. Moingeon,et al. Immune mechanisms of allergen‐specific sublingual immunotherapy , 2006, Allergy.
[26] H. Koenen,et al. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. , 2006, Blood.
[27] M. Nussenzweig,et al. Inducing and expanding regulatory T cell populations by foreign antigen , 2005, Nature Immunology.
[28] A. Rudensky,et al. Developmental regulation of Foxp3 expression during ontogeny , 2005, The Journal of experimental medicine.
[29] R. Lahesmaa,et al. Expression of human pim family genes is selectively up‐regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation , 2005, Immunology.
[30] M. Battaglia,et al. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.
[31] B. Baban,et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.
[32] A. Khoruts,et al. A model of suppression of the antigen-specific CD4 T cell response by regulatory CD25+CD4 T cells in vivo. , 2005, International immunology.
[33] P. Hammerman,et al. The Pim kinases control rapamycin-resistant T cell survival and activation , 2005, The Journal of experimental medicine.
[34] A. Singer,et al. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2 , 2005, Nature Immunology.
[35] A. Khoruts,et al. A Role for CD28 in Lymphopenia-Induced Proliferation of CD4 T Cells1 , 2004, The Journal of Immunology.
[36] H. von Boehmer,et al. In Vivo Instruction of Suppressor Commitment in Naive T Cells , 2004, The Journal of experimental medicine.
[37] D. Munn,et al. Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells1 , 2004, The Journal of Immunology.
[38] M. Dougados,et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.
[39] E. Ingulli,et al. Development of a Novel Transgenic Mouse for the Study of Interactions Between CD4 and CD8 T Cells During Graft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[40] U. Grohmann,et al. Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.
[41] J. Bluestone,et al. Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells 1 , 2003, The Journal of Immunology.
[42] J. Lohr,et al. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens , 2003, Nature Immunology.
[43] F. Ramsdell,et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.
[44] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[45] A. Khoruts,et al. Competition for self ligands restrains homeostatic proliferation of naive CD4 T cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[46] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[47] U. Grohmann,et al. CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.
[48] M. Jenkins,et al. Flow Cytometric Analysis of T Cell Receptor Signal Transduction , 2002, Science's STKE.
[49] A. Khoruts,et al. Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness1 , 2001, The Journal of Immunology.
[50] T. Laufer,et al. Major Histocompatibility Complex Class II–Positive Cortical Epithelium Mediates the Selection of Cd4+25+ Immunoregulatory T Cells , 2001, The Journal of experimental medicine.
[51] A. Khoruts,et al. Generation of Anergic and Potentially Immunoregulatory CD25+CD4 T Cells In Vivo After Induction of Peripheral Tolerance with Intravenous or Oral Antigen1 , 2001, The Journal of Immunology.
[52] A. Gingras,et al. Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.
[53] A. Naji,et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide , 2001, Nature Immunology.
[54] J. Bluestone,et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.
[55] B. Nelson,et al. The IL-2 Receptor Promotes Lymphocyte Proliferation and Induction of the c-myc, bcl-2, and bcl-x Genes Through the trans-Activation Domain of Stat51 , 2000, The Journal of Immunology.
[56] H. Lodish,et al. Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice A Direct Role for Stat5 in Bcl-XL Induction , 1999, Cell.
[57] F. Otsuka,et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. , 1999, Journal of immunology.
[58] B. Blazar,et al. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. , 1998, Journal of immunology.
[59] A. Khoruts,et al. A Natural Immunological Adjuvant Enhances T Cell Clonal Expansion through a CD28-dependent, Interleukin (IL)-2–independent Mechanism , 1998, The Journal of experimental medicine.
[60] H. Rui,et al. Two Discrete Regions of Interleukin-2 (IL2) Receptor β Independently Mediate IL2 Activation of a PD98059/Rapamycin/Wortmannin-insensitive Stat5a/b Serine Kinase* , 1997, The Journal of Biological Chemistry.
[61] T. Strom,et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.
[62] A. B. Lyons,et al. Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.